Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Coherus Bio (CHRS)

Coherus Bio (CHRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Coherus BioSciences: Q1 Earnings Snapshot

Coherus BioSciences: Q1 Earnings Snapshot

CHRS : 2.12 (-2.30%)
Why Coherus Biosciences Stock Tumbled on Thursday

The company fell well short of expectations for its fourth quarter.

CHRS : 2.12 (-2.30%)
Coherus BioSciences: Q4 Earnings Snapshot

Coherus BioSciences: Q4 Earnings Snapshot

CHRS : 2.12 (-2.30%)
Why Coherus BioSciences Stock Jumped Today

As promised, Coherus is using the proceeds of a recent divestiture to pay down debt and reduce interest expenses.

CHRS : 2.12 (-2.30%)
Why Coherus BioSciences Stock Is Sinking Today

The positive reaction to Coherus' sale of its ophthalmology franchise to Sandoz didn't last long.

CHRS : 2.12 (-2.30%)
Why Coherus Biosciences Popped Today

Coherus is divesting its non-core ophthalmology franchise.

SDZNY : 35.2300 (-2.11%)
CHRS : 2.12 (-2.30%)
Why Coherus BioSciences Stock Jumped Today

Coherus finally received FDA approval for its Udenyca OnBody injector system.

CHRS : 2.12 (-2.30%)
Cytokinetics, New York Times rise; Iovance Biotherapeutics fall, Wednesday, 12/27/2023

Stocks that are trading heavily or have substantial price changes on Wednesday: Cytokinetics, New York Times rise; Iovance Biotherapeutics fall

CYTK : 59.53 (-0.65%)
NEM : 43.74 (+2.10%)
TMUS : 164.00 (+0.26%)
FCX : 54.23 (+4.21%)
TM : 219.76 (+1.92%)
CHRS : 2.12 (-2.30%)
NYT : 48.81 (-0.06%)
2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street

These two biotech stocks could be poised for a trend reversal.

BMY : 44.03 (-0.18%)
AGEN : 10.86 (+3.43%)
CHRS : 2.12 (-2.30%)
Why Coherus BioSciences Was Plummeting This Week

The company has been punished harshly for a worse-than-expected quarter.

TFC : 39.97 (-0.45%)
CHRS : 2.12 (-2.30%)

Barchart Exclusives

Nasdaq Market Has Perfect Bullish Historical Pattern – Don't Sell in May!
"Sell in May and come back after Labor Day" is a well-known adage in the stock market that suggests investors should sell their stock holdings in May and return to the market after Labor Day in September. But, like so many market clichés, sayings that aren't supported by historical data are meaningless. An example is the upcoming Nasdaq seasonal buy with a perfect historical 15-year record. Will 2024 be the 16th year? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar